Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Taxes (2016 - 2025)

Anika Therapeutics has reported Current Taxes over the past 13 years, most recently at $65000.0 for Q1 2025.

  • Quarterly Current Taxes fell 95.64% to $65000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $65000.0 through Mar 2025, down 95.64% year-over-year, with the annual reading at $63000.0 for FY2024, 94.92% down from the prior year.
  • Current Taxes was $65000.0 for Q1 2025 at Anika Therapeutics, up from $63000.0 in the prior quarter.
  • Over five years, Current Taxes peaked at $1.5 million in Q1 2024 and troughed at $63000.0 in Q4 2024.
  • The 4-year median for Current Taxes is $814500.0 (2022), against an average of $646600.0.
  • Year-over-year, Current Taxes surged 67.6% in 2024 and then plummeted 95.64% in 2025.
  • A 4-year view of Current Taxes shows it stood at $810000.0 in 2022, then surged by 53.09% to $1.2 million in 2023, then tumbled by 94.92% to $63000.0 in 2024, then increased by 3.17% to $65000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Current Taxes are $65000.0 (Q1 2025), $63000.0 (Q4 2024), and $82000.0 (Q3 2024).